MedPath

Post market clinical follow-up study for the Pamira ICD lead family.

Withdrawn
Conditions
cardiac arrhythmias
10007521
Registration Number
NL-OMON56034
Lead Sponsor
BIOTRONIK SE & Co.KG
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Withdrawn
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

Standard indication for ICD therapy according to clinical guidelines.
Planned for de novo implantation of a BIOTRONIK ICD in combination with a
Pamira ICD lead.
Ability and willingness to use the CardioMessenger and acceptance of the
BIOTRONIK Home Monitoring® concept.
See CIP 8.3.1.

Exclusion Criteria

Mechanical tricuspid valve prosthesis or a severe tricuspid valve disease.
Cardiac surgical post-implantation procedure planned within 12 months.
See CIP 8.3.2.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The primary objective is to collect clinical data on the performance and safety<br /><br>of the Pamira lead by analyzing the Pamira related SADE-d events occurring<br /><br>during the implantation or in the 6 months thereafter.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary objective is to confirm the clinical safety by analyzing the<br /><br>Pamira-related SADE-d events occurring during the implantation or in the 3 and<br /><br>12 months thereafter, as well as the assessment of the appropriateness of right<br /><br>ventricular sensing and pacing at the 6- and 12-month FU.</p><br>
© Copyright 2025. All Rights Reserved by MedPath